Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects

被引：0
|
作者：
Katsuyuki Murase
Lucy Lee
Jiyuan Ma
Rosemary Barrett
Martin Thoolen
机构：
[1] PTC Therapeutics,
[2] Inc.,undefined
来源：
European Journal of Clinical Pharmacology | 2022年 / 78卷
关键词：
Vatiquinone; Drug-drug interactions; Pharmacokinetics; CYP inhibition; Healthy volunteers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1823 / 1831
页数：8
相关论文
共 50 条
  • [1] Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects
    Murase, Katsuyuki
    Lee, Lucy
    Ma, Jiyuan
    Barrett, Rosemary
    Thoolen, Martin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (11) : 1823 - 1831
  • [2] Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6
    Bahar, Muh Akbar
    Setiawan, Didik
    Hak, Eelko
    Wilffert, Bob
    PHARMACOGENOMICS, 2017, 18 (07) : 701 - 743
  • [3] A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF VADADUSTAT ON THE PHARMACOKINETICS OF CELECOXIB, A CYP2C9 SUBSTRATE IN HEALTHY VOLUNTEERS
    Chandorkar, Gurudatt A.
    Farzaneh-Far, Ramin
    Buch, Akshay
    Maroni, Bradley
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 197 - 197
  • [4] In vitro assessment of drug-drug interaction potential between CYP2C9 substrates and cannabinoids
    Lessard, E
    Gauvin, C
    Morin, PE
    Grudé, P
    Ducharme, J
    DRUG METABOLISM REVIEWS, 2005, 37 : 40 - 41
  • [5] An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates
    Andersson, TB
    Bredberg, E
    Ericsson, H
    Sjöberg, H
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (07) : 715 - 721
  • [6] Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor
    Xiao, Jim J.
    Nowak, Dorota
    Ramlau, Rodryg
    Tomaszewska-Kiecana, Monika
    Wysocki, Piotr J.
    Isaacson, Jeff
    Beltman, Jeri
    Nash, Eileen
    Kaczanowski, Robert
    Arold, Gerhard
    Watkins, Simon
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (01): : 58 - 65
  • [7] Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer
    Park, Gab-Jin
    Bae, Soo Hyeon
    Park, Wan-Su
    Han, Seunghoon
    Park, Min-Ho
    Shin, Seok-Ho
    Shin, Young G.
    Yim, Dong-Seok
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1043 - +
  • [8] Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions
    Shirasaka, Yoshiyuki
    Sager, Jennifer E.
    Lutz, Justin D.
    Davis, Connie
    Isoherranen, Nina
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (07) : 1414 - 1424
  • [9] Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
    Kirchheiner, J
    Bauer, S
    Meineke, I
    Rohde, W
    Prang, V
    Meisel, C
    Roots, I
    Brockmöller, J
    PHARMACOGENETICS, 2002, 12 (02): : 101 - 109
  • [10] Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro:: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism
    Shon, JH
    Yoon, YR
    Kim, MJ
    Kim, KA
    Lim, YC
    Liu, KH
    Shin, DH
    Lee, CH
    Cha, IJ
    Shin, JG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 552 - 563
12345